- Home
- EPAM vs VTRS Comparison
EPAM vs VTRS Comparison
Compare EPAM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- VTRS
- Stock Information
- Founded
- EPAM 1993
- VTRS 1961
- Country
- EPAM United States
- VTRS United States
- Employees
- EPAM N/A
- VTRS N/A
- Industry
- EPAM EDP Services
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- EPAM Technology
- VTRS Health Care
- Exchange
- EPAM Nasdaq
- VTRS Nasdaq
- Market Cap
- EPAM 14.0B
- VTRS 15.6B
- IPO Year
- EPAM 2012
- VTRS N/A
- Fundamental
- Price
- EPAM $248.27
- VTRS $12.52
- Analyst Decision
- EPAM Buy
- VTRS Hold
- Analyst Count
- EPAM 21
- VTRS 3
- Target Price
- EPAM $271.75
- VTRS $13.67
- AVG Volume (30 Days)
- EPAM 804.8K
- VTRS 9.7M
- Earning Date
- EPAM 02-13-2025
- VTRS 11-07-2024
- Dividend Yield
- EPAM N/A
- VTRS 3.83%
- EPS Growth
- EPAM N/A
- VTRS N/A
- EPS
- EPAM 7.70
- VTRS N/A
- Revenue
- EPAM $4,636,846,000.00
- VTRS $15,048,500,000.00
- Revenue This Year
- EPAM $1.99
- VTRS N/A
- Revenue Next Year
- EPAM $10.72
- VTRS N/A
- P/E Ratio
- EPAM $32.26
- VTRS N/A
- Revenue Growth
- EPAM N/A
- VTRS N/A
- 52 Week Low
- EPAM $169.43
- VTRS $9.93
- 52 Week High
- EPAM $317.50
- VTRS $13.62
- Technical
- Relative Strength Index (RSI)
- EPAM 58.30
- VTRS 47.73
- Support Level
- EPAM $239.00
- VTRS $12.07
- Resistance Level
- EPAM $253.08
- VTRS $12.74
- Average True Range (ATR)
- EPAM 6.54
- VTRS 0.33
- MACD
- EPAM -1.50
- VTRS -0.10
- Stochastic Oscillator
- EPAM 51.50
- VTRS 38.79
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.